The data presented in this study provide a tantalizing possibility for a similar synthetic lethality targeting in BER-deficient ER+ breast cancers using inhibitors of DSB repair pathway such as those targeting ATM, ATR, and DNA-PKcs that are currently undergoing pharmaceutical drug development. This evidence concerns the gene ATM and breast carcinoma.